Skip to content
Menu

Humacyte, Inc. HUMA

Full chart Compare
Set alert

Price alert · HUMA

All alert types
0.54 USD +0.04 (+8.50%)

Regular-session close

0.54 0.00 -0.29%

After hours · Nov 19, 4:00 PM ET

0.5157 Day range 0.5799
0.337 52-week range 1.53
YTD
-43.55%
1 year
-53.63%

5D -0.0627 (-10.36%)

0.50000.55000.6000FriMonTueWedThu0.5425
Market cap
150.71M
EPS (ttm)
-0.45
Shares out
128.67M
Forward P/E
-5.41
YTD return
-43.55%
1-year return
-53.63%
50-day average
4.85
200-day average
5.43
Enterprise value
580.94M
Volume
3.74M
Avg volume
5.46M
Open
0.5194
Previous close
0.50
Day's range
0.5157 – 0.5799
52-week range
0.337 – 1.53
Beta
1.47
Analysts
Strong Buy
Price target
13.71 (+2428.0%)

Key statistics

Free cash flow
-58.33M
Total cash
20.57M
Total debt
17.52M
Short % of float
20.36%

Fundamental scorecard

6 of 25 checks passed on HUMA’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 2 of 5
  • Growth 2 of 5
  • Profitability 0 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
HUMA Revenue — quarterly 1.03M
HUMA Net income — quarterly -15.54M
HUMA EPS — quarterly -0.06

Earnings

HUMA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 8, 2024Sep 1, 2024-0.26-0.33-0.07-26.92%
Aug 13, 2024Jun 1, 2024-0.23———
Aug 13, 2024Jun 1, 2024-0.23-0.27-0.04-17.39%
May 10, 2024Mar 1, 2024-0.23———
May 10, 2024Mar 1, 2024-0.23-0.29-0.06-26.09%
Mar 22, 2024Dec 1, 2023-0.25-0.24+0.01+4.00%

Upgrades / downgrades

HUMA analyst upgrades and downgrades
DateFirmActionFromTo
Dec 23, 2024BenchmarkmainBuyBuy
Dec 20, 2024D. Boral CapitalmainBuyBuy
Dec 20, 2024HC Wainwright & Co.reitBuyBuy
Nov 21, 2024D. Boral CapitalmainBuyBuy
Nov 18, 2024HC Wainwright & Co.reitBuyBuy
Nov 13, 2024HC Wainwright & Co.reitBuyBuy

About Humacyte, Inc.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
humacyte.com

News

Your note

Sign in to keep a note on HUMA — it syncs with the Stock Master app.

Insider holders

HUMA insider holders
InsiderRelationLatest transactionDateShares held
AYABUDGE, L.L.C.Beneficial Owner of more than 10% of a Class of SecuritySaleAug 20, 20238,191,140
BINDER GORDON MDirectorPurchaseMay 14, 20240
CONSTANTINO MICHAEL TDirectorPurchaseDec 3, 202416,950
DOUGAN BRADY WDirectorSaleNov 19, 20240
GREEN CHARLES BRUCEDirectorConversion of Exercise of derivative securitySep 12, 20242,400
NIKLASON LAURA EChief Executive OfficerSaleNov 19, 20240

Institution ownership

HUMA institution ownership
Holder% heldSharesValueReported
Blackrock Inc.5.99%7,539,33935.06MSep 29, 2024
Vanguard Group Inc4.02%5,058,68923.52MSep 29, 2024
State Street Corporation3.79%4,764,15522.15MSep 29, 2024
Geode Capital Management, LLC1.62%2,040,2189.49MSep 29, 2024
Millennium Management Llc1.01%1,267,5075.89MSep 29, 2024
Voloridge Investment Management, LLC1.00%1,259,9405.86MSep 29, 2024

Fund ownership

HUMA fund ownership
Holder% heldSharesValueReported
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF2.26%2,839,09513.20MSep 29, 2024
Vanguard Total Stock Market Index Fund2.06%2,592,81512.06MSep 29, 2024
iShares Russell 2000 ETF1.83%2,306,74310.73MOct 30, 2024
Vanguard Extended Market Index Fund0.98%1,232,2035.73MSep 29, 2024
Fidelity Small Cap Index Fund0.71%899,7044.18MAug 30, 2024
iShares Russell 2000 Growth ETF0.63%789,3893.67MOct 30, 2024